文献速递肿瘤 PET/CT

子宫颈鳞状细胞癌患者的18F-氟环丁烷羧酸PET/MRI与18F-FDG PET/CT对照

18F-Fluciclovine PET/MRI in a Patient With Squamous Cell Carcinoma of the Uterine Cervix Correlated With 18F-FDG PET/CT.
PubMed 文献 · Clin Nucl Med · 2020-01-01

一例32岁FIGO IIA期子宫颈浸润性鳞状细胞癌患者接受临床FDG PET/CT显示原发灶高摄取,研究性18F-氟环丁烷羧酸PET/MRI在注射后5分钟和40分钟显示原发灶摄取增高,无区域或远处转移证据;氟环丁烷羧酸PET对宫颈癌成像可能有诊断价值,潜在优势为经肾排泄导致尿液活性低,但该患者中其代谢活性低于FDG PET。

要点

  • 18F-氟环丁烷羧酸PET/MRI在宫颈癌原发灶显示摄取增高,无区域或远处转移证据。
  • 氟环丁烷羧酸经肾排泄、尿液活性低,可能对宫颈癌成像有诊断价值。
  • 该患者中氟环丁烷羧酸的代谢活性低于FDG PET。

核心结论

  • 氟环丁烷羧酸PET对宫颈癌成像可能有诊断价值,潜在优势为经肾排泄导致尿液活性低,但该患者中其代谢活性低于FDG PET。

研究设计与样本

  • 一例32岁女性FIGO IIA期子宫颈浸润性鳞状细胞癌患者的病例报告,接受临床FDG PET/CT与研究性18F-氟环丁烷羧酸PET/MRI。

主要发现

  • 临床FDG PET/CT显示原发灶强烈摄取。
  • 研究性18F-氟环丁烷羧酸PET/MRI显示原发灶在注射后5分钟和40分钟摄取增高,无区域或远处转移证据。
  • 该患者中氟环丁烷羧酸的代谢活性低于FDG PET。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 32-year-old woman with a FIGO (International Federation of Gynecology and Obstetrics) stage IIA invasive squamous cell carcinoma of the uterine cervix underwent a clinical FDG PET/CT scan, which revealed intense uptake in the primary. On research F-fluciclovine PET/MRI, the primary showed elevated fluciclovine uptake at 5 and 40 minutes after radiotracer injection, with no evidence of regional or distant metastasis. Fluciclovine PET may have diagnostic value for cervical cancer imaging with a potential advantage over FDG of minimal urinary activity from renal excretion; however, in this patient, the metabolic activity was inferior to that of FDG PET.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Nguyen NC, Moon CH, Beriwal S, et al. 18F-Fluciclovine PET/MRI in a Patient With Squamous Cell Carcinoma of the Uterine Cervix Correlated With 18F-FDG PET/CT. Clin Nucl Med. 2020. PMID: 32558719. doi:10.1097/RLU.0000000000003139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。